Article
Oncology
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Bjorn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Summary: This study compared different dosing schedules of exemestane, an aromatase inhibitor, in patients with breast cancer. The results showed that a 25mg dose taken three times weekly was as effective as a daily dose in decreasing serum estradiol levels, suggesting that this alternative schedule warrants further investigation.
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Brian M. Slomovitz, Virginia L. Filiaci, Joan L. Walker, Michael C. Taub, Karen A. Finkelstein, John W. Moroney, Aimee C. Fleury, Carolyn Y. Muller, Laura L. Holman, Larry J. Copeland, David S. Miller, Robert L. Coleman
Summary: This study evaluated the efficacy and tolerability of everolimus/letrozole and medroxyprogesterone acetate/tamoxifen in the treatment of metastatic endometrial carcinoma. The results showed that both treatment regimens demonstrated clinically meaningful efficacy in patients, especially in chemotherapy-naive patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Jooyoung Oh, Hye Sun Lee, Soyoung Jeon, Dooreh Kim, Jeong-Ho Seok, Woo-Chan Park, Jae-Jin Kim, Chang Ik Yoon
Summary: This study, using a nationwide population-based cohort, found no evidence that endocrine treatment increases the risk of depression in breast cancer patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xuan Ge, Susan E. Yost, Jin Sun Lee, Paul H. Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Samuel Chung, Christina Yeon, Daphne Stewart, Daneng Li, Swapnil Rajurkar, George Somlo, Joanne Mortimer, James Waisman, Yuan Yuan
Summary: This study investigated the safety and antitumor activity of aromatase inhibitors (AIs) in combination with immune checkpoint inhibitor pembrolizumab in patients with HR+ HER2(-) metastatic breast cancer. The combination was well tolerated, but clinical activity was not significantly different from the use of AI alone.
Article
Chemistry, Multidisciplinary
Shwetakshi Sharma, Priya Gupta, Annie Gupta, S. M. Kawish, Zeenat Iqbal, Divya Vohora, Kanchan Kohli
Summary: In this study, a validated HPLC method was developed for the simultaneous quantification of exemestane and genistein in combination. The method showed good linearity within the range of 5-110 μg/mL for both drugs. The developed method was found to be suitable for the identification of both drugs simultaneously. Evaluation: 7 out of 10.
Article
Pathology
Kimberly Dessources, Kathryn M. Miller, Elizabeth Kertowidjojo, Arnaud Da Cruz Paula, Youran Zou, Pier Selenica, Edaise M. da Silva, Ryma Benayed, Charles W. Ashley, Nadeem R. Abu-Rustum, Snjezana Dogan, Robert A. Soslow, Martee L. Hensley, Britta Weigelt, Sarah Chiang
Summary: High-grade endometrial stromal sarcomas (HGESS) are more aggressive and have higher rates of resistance to endocrine therapy than low-grade endometrial stromal sarcomas (LGESS). The ESR1 p.Y537S hotspot mutation may be associated with endocrine resistance in LGESS with histologic high-grade transformation following hormonal therapy.
Review
Chemistry, Medicinal
Ankita Sood, Damanpreet Kaur Lang, Rajwinder Kaur, Balraj Saini, Sandeep Arora
Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Caroline Bailleux, Antoine Arnaud, Jean-Sebastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoit You, Laetitia Stefani, Claire Garnier Tixidre, Helene Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Remy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
Summary: The CHEOPS trial aimed to evaluate the benefit of adding aromatase inhibitor (AI) to metronomic chemotherapy for pre-treated, HR+/HER2- metastatic breast cancer patients. The study found that although the addition of AI to oral vinorelbine showed a non-significant improvement in progression-free survival, several unexpected serious adverse events were reported. The question of hormonal treatment and chemotherapy combination remains open.
Review
Oncology
Vincent M. Wagner, Floor J. Backes
Summary: Endometrial cancer is a common gynecologic cancer with poor prognosis in recurrent cases. Hormonal therapy, including progesterones and agents targeting the estrogen pathway, is an effective option for patients with low-grade hormone receptor-positive disease who cannot tolerate or prefer to avoid cytotoxic chemotherapy or other targeted therapies. Molecular profiling and ongoing trials are exploring novel hormonal therapy agents.
Article
Oncology
C. C. B. Post, A. M. Westermann, I. A. Boere, P. O. Witteveen, P. B. Ottevanger, G. S. Sonke, R. Lalisang, H. Putter, E. Meershoek-Klein Kranenbarg, J. P. B. M. Braak, C. L. Creutzberg, T. Bosse, J. R. Kroep
Summary: The combination of PD-L1 and PARP inhibitors for advanced endometrial cancer showed good tolerability in this trial, however, it did not meet the predefined efficacy endpoint. Some patients had progression-free survival at 6 months, with an objective response rate of 16%, a median progression-free survival of 3.4 months, and a median overall survival of 8.0 months.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Endocrinology & Metabolism
Tara Hyder, Christopher C. Marino, Sasha Ahmad, Azadeh Nasrazadani, Adam M. Brufsky
Summary: Aromatase inhibitors (AIs) are essential in the management of hormone receptor-positive (HR+) breast cancer, but their use is limited by the musculoskeletal adverse effects known as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS), which includes bone loss and arthralgias. The pathophysiology of AIMSS is not fully understood, but is proposed to be related to estrogen deprivation in the musculoskeletal and nervous systems.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Yiwei Tong, Siyi Zhu, Weiguo Chen, Xiaosong Chen, Kunwei Shen
Summary: The purpose of this study was to evaluate the influence of obesity on clinicopathological characteristics of breast cancer and to explore its effects on prognosis and endocrine therapy in Chinese patients. The results showed that obesity was associated with a higher risk of comorbidities and PR-positive tumors, but not with overall disease recurrence or survival in the whole population. However, obesity was found to be associated with worse relapse-free survival and overall survival in the luminal A subtype, but not in the luminal B subtype. Obesity did not impact the effectiveness of endocrine therapy in both Tamoxifen and aromatase inhibitor groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Norikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, Akihiko Shimomura, Masataka Sawaki, Min-Jung Lee, Akira Yuno, Jane Trepel, Ryoko Kimura, Yozo Nishimura, Shigehira Saji, Hiroji Iwata
Summary: This study examined the safety, efficacy, and pharmacokinetics of Entinostat monotherapy and combined Entinostat/exemestane in Japanese patients with endocrine therapy-resistant breast cancer. The results showed that both treatments were well tolerated, with some patients achieving stable disease for more than 6 months. Further investigation on the correlation between pharmacokinetics and Ac-K in peripheral blood CD19+ B cells, as well as T-cell activation markers, is warranted.
Article
Endocrinology & Metabolism
Gerhard Binder, Akie Nakamura, Roland Schweizer, Tsutomu Ogata, Maki Fukami, Keisuke Nagasaki
Summary: The study on the long-term treatment effects of aromatase inhibitor in boys with AEXS showed that early initiation of anastrozole treatment can promote adult height in these patients, suggesting a potential benefit of long-term inhibition of aromatase.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Markus K. H. Wiedmann, Cathrine Brunborg, Antonio Di Ieva, Kristina Lindemann, Tom B. Johannesen, Lars Vatten, Eirik Helseth, John A. Zwart
Article
Oncology
Kamil Zalewski, Kristina Lindemann, Michael J. Halaska, Ignacio Zapardiel, Rene Laky, Elisabeth Chereau, David Lindquist, Stephan Polterauer, Vladislav Sukhin, Polat Dursun
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2017)
Article
Oncology
Kristina Lindemann, Peey-Sei Kok, Martin Stockler, Peter Sykes, Alison Brand
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2017)
Review
Oncology
Kristina Lindemann, Peey-Sei Kok, Martin Stockler, Ken Jaaback, Alison Brand
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2017)
Article
Oncology
Kristina Lindemann, Bo Gao, Cristina Mapagu, Sian Fereday, Catherine Emmanuel, Kathryn Alsop, Nadia Traficante, Paul R. Harnett, David D. L. Bowtell, Anna deFazio
GYNECOLOGIC ONCOLOGY
(2018)
Article
Oncology
Kristina Lindemann, Philip J. Beale, Emma Rossi, Jeff C. Goh, Michelle M. Vaughan, Meaghan E. Tenney, Julie K. Martyn, Dirkje Sommeijer, Jose L. Iglesias, Gabriel Kremmidiotis, Jeremy Simpson, Elizabeth Doolin, Tina C. Lavranos, Annabell Leske, Anneso S. Veillard, David Espinoza, Martin R. Stockler, Danny Rischin
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2019)
Article
Oncology
Elisa Piovano, Annamaria Ferrero, Paolo Zola, Christian Marth, Mansoor Raza Mirza, Kristina Lindemann
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2019)
Article
Oncology
Elisabeth Smogeli, Milada Cvancarova, Yun Wang, Ben Davidson, Gunnar Kristensen, Kristina Lindemann
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2018)
Article
Obstetrics & Gynecology
Ingvild Vistad, Kristina Lindemann, Anne G. Bentzen, Alv A. Dahl, Rita Steen, Cecilie Kiserud
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
(2020)
Article
Oncology
K. Lindemann, L. Martinsson, S. Kaasa, D. Lindquist
Article
Oncology
Anette Stolberg Kargo, Angela Coulter, Kristina Lindemann, Pernille Tine Jensen, Niels Henrik Hjollund, Berit Jul Mosgaard, Karina Dahl Steffensen
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2020)
Article
Oncology
Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, Alexander Reuss, Andres Redondo, Kristina Lindemann, Christian Kurzeder, Edgar Petru, Florian Heitz, Jalid Sehouli, Nikolaus Degregorio, Pauline Wimberger, Alexander Burges, Nadin Cron, Jonathan Ledermann, Domenica Lorusso, Xavier Paoletti, Frederik Marme
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2020)
Review
Medicine, General & Internal
Felicia Roncolato, Kristina Lindemann, Melina L. Wilson, Julie Martyn, Linda Mileshkin
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2019)
Article
Oncology
Lucas Minig, Florian Heitz, David Cibula, Jamie N. Bakkum-Gamez, Anna Germanova, Sean C. Dowdy, Eleftheria Kalogera, Ignacio Zapardiel, Kristina Lindemann, Philipp Harter, Giovanni Scambia, Marco Petrillo, Cristina Zorrero, Vanna Zanagnolo, Jose Miguel Cardenas Rebollo, Andreas du Bois, Christina Fotopoulou
ANNALS OF SURGICAL ONCOLOGY
(2017)
Article
Oncology
Kristina Lindemann, Emma Gibbs, Elisabeth Avall-Lundqvist, Rene dePont Christensen, Kathrine Woie, Marten Kalling, Annika Auranen, Seija Grenman, Thomas Hoegberg, Per Rosenberg, Tone Skeie-Jensen, Elisabet Hjerpe, Anne Dorum, Val Gebski, Gunnar Kristensen
BRITISH JOURNAL OF CANCER
(2017)